From Name:
From Email:
To Name:
To Email:

Optional Message:


Biogen's potentially game-changing Alzheimer's drug still faces an uphill battle with the FDA

from CNBC

Biogen pleased shareholders this week after it presented more data on its late-stage Alzheimer's drug, aducanumab. Shares of the biotech firm closed up 3.41% as analysts pointed to a lack of any new negatives compared with the aducanumab results released in October, which may increase the drug's odds of approval with the Food and Drug Administration. more


Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063